Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

Core Insights - Ernexa Therapeutics is transitioning from research to clinical-stage development, focusing on innovative cell therapies for advanced cancer and autoimmune diseases [1][3] - The company has expanded its Scientific Advisory Board to include distinguished medical leaders to guide its clinical programs [2][3] Company Developments - Ernexa has strengthened its financial position, which supports its strategy to accelerate lead programs toward clinical trials [1] - The newly formed advisory board will assist in trial design, biomarker development, and regulatory engagement as the company prepares for IND-enabling studies [3][6] Advisory Board Composition - Dr. Amir Anthony Jazaeri, an expert in gynecologic oncology, will guide the ovarian cancer program [2][4] - Dr. Anna Helena Jonsson, a specialist in autoimmune diseases, will lead the translational strategy for the autoimmune pipeline [2][5] Product Focus - The lead product, ERNA-101, aims to activate and regulate the immune system to target cancer cells, with an initial focus on ovarian cancer [8] - ERNA-102 is designed to address inflammation in autoimmune diseases [8] Scientific Approach - Ernexa's core technology involves engineering induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), providing scalable treatment options [7]